Live probiotic trial to reduce frequent bowel movements
Part of Digestive system clinical trials.
This Phase 1/2 study tests EXE-346, a live probiotic given to people with an IPAA pouch who have frequent bowel movements. It aims to see if the treatment can safely lower how often you have bowel movements each day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 70 years old at screening (for Phase 1b) or at least 18 (for Phase 2).
- Have had an IPAA pouch placed at least 6 months ago.
- Have had a pouch camera exam (pouchoscopy) within the last 12 months (and for Phase 2, one during screening).
- During screening, have at least 10 bowel movements per day on average and complete at least 7 days of bowel-movement diary entries.
- For people who could become pregnant: use reliable birth control and be not pregnant or breastfeeding at screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a natural supplement called Aquamin (a red algae-derived mineral source) can help prevent inflammation in people who have had surgery for ulcerative colitis and now have a J-pouch. It aims to see if this supplement reduces pouch inflammation and related symptoms.
This study tests whether the medicine tirzepatide (Mounjaro) can reduce frequent bowel movements in people with a J-pouch after ulcerative colitis surgery. It aims to improve quality of life by decreasing the number of daily bowel movements.
This trial tests if etrasimod can prevent pouchitis, which is inflammation of the surgically created internal pouch, in people who have had their colon removed due to ulcerative colitis. If you are at high risk for pouchitis or have had only one episode, this study may help keep your pouch healthy.
This early-phase study tests fecal microbiota transplant (a stool-based treatment) to improve chronic pouchitis symptoms in adults after UC-related surgery. It may help by changing gut bacteria, especially for people who need ongoing antibiotics or keep having flare-ups.
This trial tests whether a fecal microbiota transplantation (FMT), which transfers healthy bacteria from a donor into your gut, can reduce severe irritable bowel syndrome (IBS) symptoms. FMT is being studied as a possible new treatment for people with IBS that hasn't improved with other treatments.
This study tests whether a daily probiotic supplement (a beneficial bacteria) can improve the protective lining of the gut and reduce leakage in people with inflammatory bowel disease (IBD). It involves taking the supplement for a period of time and undergoing some measurements of gut health.
Hear when a new Ileal Pouch trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.